Investor's Calendar
Last News

ROVI reports operating revenue growth of 3% for the first nine months of the first post-pandemic year
5 min
08 Nov, 2023

For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in...
3 min
04 Aug, 2023

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the...
1 min
28 Jul, 2023
Public statements sent to CNMV
ESG
Discover what ROVI is doing to become a more sustainable company
CORPORATE GOVERNANCE
Find out more about ROVI’s main governing bodies
Information for investors

Marta Campos
Head of Investor Relations

Antonio Marquina
Investor Relations
